AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8138763
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of normal serum cholesterol concentration (< 5.2 mmol/l) after education intervention
Trial: 3273841
Drug: Antenatal phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal phenobarbital (700 mg loading dose, followed by daily maintenance until delivery)
Trial: 28346285
Drug: Prompt revascularization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt revascularization with percutaneous coronary intervention or coronary artery bypass grafting in addition to intensive medical therapy
Trial: 21621227
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) intervention called Managing Anxiety and Depression using Education and Skills (MADES)
Trial: 14673543
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (88 mEq in 50 ml) administered as a slow bolus 1 hour prior to (201)Tl injection
Trial: 9433652
Drug: grepafloxacin 600
RxNorm normalized name: grepafloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: grepafloxacin 600 mg after fasting or after consumption of a standard high-fat meal
Trial: 9433652
Drug: grepafloxacin 400
RxNorm normalized name: grepafloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: grepafloxacin 400 mg alone or after infusion of famotidine 20 mg
Trial: 11103175
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg kg‐1
Trial: 8499200
Drug: Pethidine 0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.67 mg kg‐1
Trial: 8499200
Drug: Methadone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 0.1 mg kg‐1
Trial: 30544211
Drug: Maternal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal intervention with fish-oil capsules (215 mg DHA + 285 mg EPA)
Trial: 30544211
Drug: Child intervention
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child intervention with fish-oil-enriched complementary food (169 mg DHA + 331 mg EPA)
Trial: 28651304
Drug: Rifaximin and
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin and Propranolol combination therapy
Trial: 2049686
Drug: Propranolol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol monotherapy
Trial: 19738166
Drug: Panitumumab or
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab or Cetuximab (EGFR-targeted monoclonal antibodies)
Trial: 12760990
Drug: Fentanyl effect-site
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effect-site concentration of 0.8 ng/mL
Trial: 12760990
Drug: Fentanyl effect-site
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effect-site concentration of 1.0 ng/mL
Trial: 12760990
Drug: Fentanyl effect-site
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effect-site concentration of 1.4 ng/mL
Trial: 12760990
Drug: Fentanyl effect-site
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effect-site concentration of 2.0 ng/mL
Trial: 12760990
Drug: Fentanyl effect-site
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effect-site concentration of 3.0 ng/mL
Trial: 10998082
Drug: Triflusal (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (600 mg day‐1 for 5 days)
Trial: 9417748
Drug: Reviparin (7000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reviparin (7000 U bolus before PTCA, followed by 10,500 U infusion over 24 hours, then 3500 U s.c. twice a day for 28 days)
Trial: 9417748
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10,000 U unfractionated heparin bolus followed by 24,000 U infusion over 24 hours, then 28 days of s.c. placebo injections)
Trial: 8171218
Drug: Rifaximin cream
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin cream
Trial: 8171218
Drug: Oxytetracycline cream
RxNorm normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytetracycline cream
Trial: 3463571
Drug: 0.02% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% chlorhexidine (CH) as the irrigating solution
Trial: 3463571
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as the irrigating solution
Trial: 30157388
Drug: Ibudilast (≤100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (≤100 mg daily)
Trial: 24614693
Drug: Polyphenol-rich whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich whole food supplement (blend of pomegranate, green tea, broccoli, and turmeric)
Trial: 23512638
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg (non-Chinese)
Trial: 23512638
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg (Chinese)
Trial: 23512638
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg (Chinese)
Trial: 23512638
Drug: Ustekinumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (both doses in Chinese)
Trial: 20693186
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing algorithm for warfarin treatment
Trial: 20693186
Drug: Clinical information
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical information only dosing algorithm for warfarin treatment
Trial: 18030007
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy prior to external beam radiation therapy
Trial: 18030007
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy prior to prostatectomy
Trial: 18030007
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy for 6 or 8 months prior to prostatectomy
Trial: 18030007
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy using docetaxel before prostatectomy
Trial: 11675332
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m² on days 1-5)
Trial: 11675332
Drug: Cyclophosphamide, doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, doxorubicin, and prednisone (CAP; 750 mg/m² cyclophosphamide and 25 mg/m² doxorubicin on day 1 and 40 mg/m² prednisone on days 1-5)
Trial: 9629509
Drug: High-dose pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pancreatic enzyme treatment (Panzytrat, 20,000 units of lipase, 18,000 units of amylase, and 1000 units of protease per capsule, 18 capsules daily for 4 weeks)
Trial: 9629509
Drug: High-dose pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pancreatic enzyme treatment
Trial: 7931188
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment (n = 11)
Trial: 3364761
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with epinephrine (5 micrograms/ml)
Trial: 3364761
Drug: 0.375% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% bupivacaine with epinephrine (5 micrograms/ml)
Trial: 2265168
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with epinephrine (5 micrograms/ml)
Trial: 29452204
Drug: Interferon‐α (IFN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐α (IFN) monotherapy or combination therapy of IFN and lamivudine (LAM)
Trial: 27105868
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg resveratrol
Trial: 31891746
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg resveratrol
Trial: 24587636
Drug: Recombinant streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant streptokinase (rSK) 200000 IU, administered rectally every 6 hours for 48 hours.
Trial: 24587636
Drug: Phenylephrine-based suppositories
RxNorm normalized name: phenylephrine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine-based suppositories (0.25%), administered rectally up to a maximum of 5 days (20 suppositories).
Trial: 24587636
Drug: Phenylephrine-based suppositories
RxNorm normalized name: phenylephrine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine-based suppositories (0.25%)
Trial: 17135753
Drug: Oral cefatrizine
RxNorm normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cefatrizine (3 doses of 1 g every 12 hours)
Trial: 10437748
Drug: Docetaxel (Taxotere)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (Taxotere) 100 mg/m2 every 3 weeks in neoadjuvant chemotherapy
Trial: 10437748
Drug: Cisplatin-based induction
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based induction chemotherapy
Trial: 8560051
Drug: lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lysine acetylsalicylate (1800 mg)
Trial: 8560051
Drug: ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac (30 mg)
Trial: 8560051
Drug: diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac (75 mg)
Trial: 19740550
Drug: Standard Rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Rehabilitation Treatment (SRT) + Computer‐aided Cognitive Remediation Treatment (CRT)
Trial: 19740550
Drug: Standard Rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Rehabilitation Treatment (SRT) + Placebo Training
Trial: 15026791
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate 50 mg
Trial: 9820262
Drug: Active hydroxycitric
RxNorm normalized name: hydroxycitric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active hydroxycitric acid (1500 mg per day)
Trial: 7697476
Drug: Other nonsteroidal
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other nonsteroidal antiinflammatory drugs (aspirin, salsalate, salicylamide, lysine acetylsalicylate, acetaminophen, dipyrone, propyfenazone)
Trial: 105164
Drug: Low-dose continuous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose continuous insulin infusion
Trial: 105164
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous bolus insulin
Trial: 26362541
Drug: Topical medication
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medication (ocular hypotensive therapy)
Trial: 23237583
Drug: Intrapregnancy non‐surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapregnancy non‐surgical periodontal treatment
Trial: 23237583
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (deferred treatment until after delivery)
Trial: 20945744
Drug: Combination bleaching
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination bleaching with 38% and 9.5% hydrogen peroxide gels (G II)
Trial: 20945744
Drug: No bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bleaching (G I)
Trial: 20945744
Drug: Combination bleaching
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination bleaching with sodium ascorbate (G IV)
Trial: 20945744
Drug: Bleaching similar
RxNorm normalized name: Antigonadotropins and similar agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching similar to G II and restored after one week (G III)
Trial: 8638454
Drug: 75g oral
RxNorm normalized name: Mesalamine 0.375g Oral capsule, biphasic release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75g oral glucose tolerance test (OGTT) performed first
Trial: 8638454
Drug: 50g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50g oral glucose tolerance test (OGTT)
Trial: 1993488
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole 3 days a week
Trial: 30901344
Drug: Oral rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral rifampicin and trimethoprim/sulfamethoxazole for 21 days (arm A)
Trial: 29972753
Drug: Patisiran (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran (0.3 mg/kg IV every 3 weeks)
Trial: 24268548
Drug: Cocaine use
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine use during treatment
Trial: 17609909
Drug: Baoshen Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baoshen Mixture (BSM) given orally thrice a day, 150 mL every time for 15 successive days
Trial: 12577352
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (Control group)
Trial: 17609909
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received one cycle of chemotherapy program of 28‐30 days with conventional hydratization, alkalization and chloridization
Trial: 17378193
Drug: Mild moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild moxibustion combined with cupping therapy
Trial: 15622367
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) 1 g with normal saline before and after angiography
Trial: 15622367
Drug: NAC (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC (i.v. at 1 g)
Trial: 10874267
Drug: Intravenous RPR
RxNorm normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous RPR 109891
Trial: 10874267
Drug: Oral RPR
RxNorm normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral RPR 109891
Trial: 10874267
Drug: Intravenous plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plus oral RPR 109891
Trial: 19155764
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (including cilostazol)
Trial: 17704423
Drug: mFU/LV (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFU/LV (monthly regimen)
Trial: 11230476
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Trial: 11230476
Drug: Six courses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Trial: 9746385
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg (n = 218)
Trial: 9746385
Drug: E2/NETA (17beta‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA (17beta‐oestradiol 2 mg plus norethisterone acetate 1 mg) (n = 219)
Trial: 2894492
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 500 and 2000 micrograms thrice in 1 day
Trial: 2894492
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 750 micrograms thrice daily for 14 days
Trial: 30788847
Drug: Ticagrelor (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (60 mg twice daily, reduced from 90 mg twice daily)
Trial: 30788847
Drug: Placebo (on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (on top of low dose aspirin)
Trial: 25639879
Drug: Submicron indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submicron indomethacin 40 mg
Trial: 25639879
Drug: Submicron indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submicron indomethacin 20 mg
Trial: 22384544
Drug: Xuezhikang (XZK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (XZK) at a daily dose of 1.2 g, twice daily (large dose group)
Trial: 22384544
Drug: Xuezhikang (XZK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (XZK) at a daily dose of 0.6 g, twice daily (normal dose group)
Trial: 22384544
Drug: Xuezhikang (XZK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (XZK) (both doses)
Trial: 16721690
Drug: IV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and III L pit SAs
Trial: 10601068
Drug: Somatostatin plus
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin plus isosorbide 5-mononitrate (250 microg/hour + 40 mg/12 hours)
Trial: 1313860
Drug: eight‐drugs‐in‐one‐day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eight‐drugs‐in‐one‐day
Trial: 2427983
Drug: Chemotherapy (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (4 courses + 20 Gy EF)
Trial: 2427983
Drug: 6 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 courses chemotherapy + 20 Gy IF
Trial: 2427983
Drug: Consolidation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation therapy 20 Gy IF
Trial: 2427983
Drug: 2 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 courses chemotherapy
Trial: 30055903
Drug: Apomorphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine infusion (mean final dose 4·68 mg/h)
Trial: 25047762
Drug: A combination
RxNorm normalized name: Enema combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of nuclear β-catenin and atypical scores
Trial: 10972367
Drug: Diuretics and
RxNorm normalized name: Low-ceiling diuretics and potassium-sparing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics and beta-blockers
Trial: 10558453
Drug: Nitrendipine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (in combination with other antihypertensive drugs)
Trial: 7181807
Drug: Transdermal therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapeutic system‐scopolamine (1.0 mg over 3 days)
Trial: 7181807
Drug: Transdermal therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapeutic system‐scopolamine (second treatment regimen)
Trial: 7181807
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four treatments)
Trial: 25337966
Drug: Adductor Canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor Canal (AC) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Trial: 25337966
Drug: Peri-saphenous branch
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-saphenous branch of the descending genicular artery (Peri-SBDGA) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Trial: 23810152
Drug: Pasteurized raw
RxNorm normalized name: raw sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasteurized raw whole egg powder (1 teaspoon daily from 4 to 8 months)
Trial: 23810152
Drug: Rice powder
RxNorm normalized name: White rice powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice powder (1 teaspoon daily from 4 to 8 months)
Trial: 21675058
Drug: Daily Sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Sedative Interruption (DSI)
Trial: 8015504
Drug: dl-norgestrel alone
RxNorm normalized name: Norgestrel
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-norgestrel alone (0.075 mg/day) continuously for two cycles